Kathleen A. Maguire-Zeiss
Department of Neuroscience
Georgetown University Medical Center
Kathleen A. Maguire-Zeiss has not added Biography.
If you are Kathleen A. Maguire-Zeiss and would like to personalize this page please email our Author Liaison for assistance.
Somatic mosaic approaches and the aging brain.
Neurobiology of aging Sep-Oct, 2002 | Pubmed ID: 12392799
Convergent pathobiologic model of Parkinson's disease.
Annals of the New York Academy of Sciences Jun, 2003 | Pubmed ID: 12846984
Safety of viral vectors for neurological gene therapies.
Current opinion in molecular therapeutics Oct, 2004 | Pubmed ID: 15537048
Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
Brain research. Molecular brain research Mar, 2005 | Pubmed ID: 15790526
Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector.
Molecular therapy : the journal of the American Society of Gene Therapy Mar, 2006 | Pubmed ID: 16412694
Identification of human alpha-synuclein specific single chain antibodies.
Biochemical and biophysical research communications Nov, 2006 | Pubmed ID: 16973126
Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival.
Brain research Feb, 2007 | Pubmed ID: 17196186
Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium.
Neurobiology of aging Nov, 2008 | Pubmed ID: 17521776
Synuclein activates microglia in a model of Parkinson's disease.
Neurobiology of aging Nov, 2008 | Pubmed ID: 17537546
Gazing into the future: Parkinson's disease gene therapeutics to modify natural history.
Experimental neurology Jan, 2008 | Pubmed ID: 18035353
alpha-Synuclein: a therapeutic target for Parkinson's disease?
Pharmacological research : the official journal of the Italian Pharmacological Society Nov-Dec, 2008 | Pubmed ID: 18840530
Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology Sep, 2009 | Pubmed ID: 18931916
Mutant alpha-synuclein overexpression mediates early proinflammatory activity.
Neurotoxicity research Oct, 2009 | Pubmed ID: 19526281
Gene therapy in Parkinson's disease: rationale and current status.
CNS drugs Mar, 2010 | Pubmed ID: 20155994
Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) Aug, 2010 | Pubmed ID: 20549523
Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability.
The European journal of neuroscience Jul, 2010 | Pubmed ID: 20550572
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.
Nature medicine Sep, 2010 | Pubmed ID: 20729864
Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance.
Neurotoxicity research Nov, 2011 | Pubmed ID: 21735318
α-Synuclein Alters Toll-Like Receptor Expression.
Frontiers in neuroscience , 2011 | Pubmed ID: 21747756
Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.
Parkinsonism & related disorders Jan, 2012 | Pubmed ID: 22166424
Matrix metalloproteinase dependent cleavage of cell adhesion molecules in the pathogenesis of CNS dysfunction with HIV and methamphetamine.
Current HIV research Jul, 2012 | Pubmed ID: 22591362
Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology Mar, 2013 | Pubmed ID: 23054368
Parkinson's disease.
Sub-cellular biochemistry , 2012 | Pubmed ID: 23225012
Development of Inducible Leucine-rich Repeat Kinase 2 (LRRK2) Cell Lines for Therapeutics Development in Parkinson's Disease.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics Aug, 2013 | Pubmed ID: 23963789
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved